Dr. Stephanie Tsai
Claim this profileLoyola University Medical Center
Area of expertise
Acute Myeloid Leukemia
Stephanie Tsai has run 6 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
Intestinal Maturation
Stephanie Tsai has run 4 trials for Intestinal Maturation. Some of their research focus areas include:
Affiliated Hospitals
Loyola University Medical Center
Loyola University Cardinal Bernardin Cancer Center
Clinical Trials Stephanie Tsai is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting
1 award
Phase 2
7 criteria
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting
1 award
Phase 2
17 criteria
More about Stephanie Tsai
Clinical Trial Related
7 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Stephanie Tsai has experience with
- Azacitidine
- Cytarabine
- Venetoclax
- Daunorubicin Hydrochloride
- Blinatumomab
- Inotuzumab Ozogamicin
Breakdown of trials Stephanie Tsai has run
Acute Myeloid Leukemia
Intestinal Maturation
Burkitt's Leukemia
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephanie Tsai specialize in?
Stephanie Tsai focuses on Acute Myeloid Leukemia and Intestinal Maturation. In particular, much of their work with Acute Myeloid Leukemia has involved PML-RARA negative patients, or patients who are FLT3 positive.
Is Stephanie Tsai currently recruiting for clinical trials?
Yes, Stephanie Tsai is currently recruiting for 5 clinical trials in Maywood Illinois. If you're interested in participating, you should apply.
Are there any treatments that Stephanie Tsai has studied deeply?
Yes, Stephanie Tsai has studied treatments such as Azacitidine, Cytarabine, Venetoclax.
What is the best way to schedule an appointment with Stephanie Tsai?
Apply for one of the trials that Stephanie Tsai is conducting.
What is the office address of Stephanie Tsai?
The office of Stephanie Tsai is located at: Loyola University Medical Center, Maywood, Illinois 60153 United States. This is the address for their practice at the Loyola University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.